AngioDynamics (ANGO) Tops Q3 EPS by 4c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance
March 30, 2021 7:00 AM EDTFiscal 2021 Third Quarter Highlights
Net sales of $71.2 million increased 2.0% compared to the prior-year quarter Gross margin of 54.1%, a decline of 370 basis points year over year GAAP loss per share of $0.09 and adjusted earnings per share of $0.02 Cash and cash equivalents on February 28, 2021 were $54.5 million The Company is raising its fiscal year 2021 guidance. The Company now expects net sales between $285 and $288 million and fiscal year 2021 adjusted earnings per share between $0.04 and $0.06LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ:... More
